Beijing-based biopharmaceutical company China Biologic Products Holdings Inc. appointed Bing Li as its CEO.
Li replaces Zhijun Tong, the blood plasma-based biopharmaceutical company's acting CEO. Tong will continue as an executive director and president of the company.
Li rejoined the China Biologic board on July 25, having previously been a director of the company from February 2011 to May 2014.
The new CEO has experience as managing director of Fosun Group, a China-based international conglomerate and investment company, from March 2016 to December 2017, and a vice president of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., a Chinese pharmaceutical company, from May 2014 to February 2016.